SYNTHESIS-TO-CLINIC Trademark

Trademark Overview

On Friday, November 5, 2021, a trademark application was filed for SYNTHESIS-TO-CLINIC with the United States Patent and Trademark Office. The USPTO has given the SYNTHESIS-TO-CLINIC trademark a serial number of 79336901. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Tuesday, March 26, 2024. This trademark is owned by Quotient Sciences Ltd. The SYNTHESIS-TO-CLINIC trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research services relating to the pharmaceutical, biotechnology and nutraceutical industry
synthesis-to-clinic

General Information

Serial Number79336901
Word MarkSYNTHESIS-TO-CLINIC
Filing DateFriday, November 5, 2021
Status681 - PUBLICATION/ISSUE REVIEW COMPLETE
Status DateTuesday, March 26, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 30, 2024

Trademark Statements

Goods and ServicesResearch services relating to the pharmaceutical, biotechnology and nutraceutical industry

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, April 4, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameQuotient Sciences Ltd
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGB

Trademark Events

Event DateEvent Description
Wednesday, April 10, 2024NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, April 10, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, April 10, 2024NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Monday, March 25, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 28, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, February 27, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 27, 2024TEAS REQUEST FOR RECONSIDERATION RECEIVED
Saturday, September 16, 2023NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Wednesday, August 30, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, August 30, 2023NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Monday, August 28, 2023NOTIFICATION OF FINAL REFUSAL EMAILED
Monday, August 28, 2023FINAL REFUSAL E-MAILED
Monday, August 28, 2023FINAL REFUSAL WRITTEN
Wednesday, June 14, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, June 13, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, June 13, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, March 1, 2023ASSIGNED TO EXAMINER
Wednesday, January 4, 2023REFUSAL PROCESSED BY IB
Tuesday, December 13, 2022NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, December 13, 2022REFUSAL PROCESSED BY MPU
Friday, September 30, 2022NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, September 29, 2022NON-FINAL ACTION WRITTEN
Wednesday, September 28, 2022NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Wednesday, August 24, 2022NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, August 23, 2022NON-FINAL ACTION WRITTEN
Wednesday, August 17, 2022ASSIGNED TO EXAMINER
Friday, April 8, 2022APPLICATION FILING RECEIPT MAILED
Monday, April 4, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, March 31, 2022SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

clinic synthesis nutraceutical industry biotechnology pharmaceutical services relating research